Home › Trials › NCT05991245
Clinical trial No longer in our active list Observational Ages 18 and up

National cohort study on renal and systemic thrombotic microangiopathy

Official title: French National Cohort MATRIX "Renal and Systemic Thrombotic Microangiopathy"

Run by University Hospital, Tours · NCT05991245 · Data updated 2026-05-14

This study is no longer in our active list. It may have stopped recruiting or finished. The details below are as of 2026-05-14 and are kept for reference. Check ClinicalTrials.gov for its current status, or see similar studies below.

This study is trying to understand rare diseases that cause blood clots and kidney problems in adults to find better ways to diagnose and treat them.

Quick facts

Study typeObservational
Ages18 Years and up
SexAll
Enrollment1000 (estimated)
SponsorUniversity Hospital, Tours
Academic / other
Locations1 site (Tours)
Trial IDNCT05991245 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates for this study are adults aged 18 and older who have undergone renal biopsy for impaired renal function and exhibit symptoms of systemic thrombotic microangiopathy.

Probably not a fit

Patients who have undergone kidney transplantation will not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to investigate thrombotic microangiopathies (TMAs), a rare group of diseases that can lead to serious renal and systemic complications. By collecting data from over 20 centers over a period of more than 10 years, the study seeks to clarify the pathophysiology, optimal management, and prognosis of TMAs, particularly focusing on the differences between renal-limited and systemic TMAs. The study will include adult patients who have undergone renal biopsies for impaired renal function and will analyze various clinical parameters to better understand the disease's impact. The goal is to improve diagnostic workups and patient outcomes through comprehensive data collection and analysis.

Why it matters

Potential benefit: If successful, this study could lead to improved diagnosis and management strategies for patients suffering from thrombotic microangiopathies.

How similar studies have gone: While there have been studies on thrombotic microangiopathies, this multicenter approach with a focus on comprehensive diagnostic workups is relatively novel.

Who can join: the full rules

Show full inclusion / exclusion criteria 
Inclusion Criteria:

1. Adult patients 18 years of age or older
2. Who have undergone renal biopsy of the native kidney for impaired renal function between 2009 and July 2022.
3. Presence of classically defined systemic MAT (most of the following parameters: elevated LDH, decreased haptoglobin, schizocytes, thrombocytopenia and anemia) AND/OR presence of arteriolar or glomerular renal MAT as indicated by the pathologist (including endothelial turgor, mesangiolysis, double contours, presence of thrombi, fibrinoid necrosis of the arterial wall).

Exclusion Criteria:

1. Kidney transplantation

Where it's running

  • Department of Nephrology, University Hospital of Tours
    Tours, France     Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
View on ClinicalTrials.gov ↗ Find more trials like this →
Browse more
Thrombotic Microangiopathy 2Acute Kidney Injury 217Hemolytic-Uremic Syndrome 3Kidney Diseases 52University Hospital, Tours 44
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.